Adaptive Biotechnologies (ADPT) Total Non-Current Liabilities (2018 - 2026)

Adaptive Biotechnologies has disclosed Total Non-Current Liabilities across 9 years of filings, most recently posting $490.0 million for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities rose 54.53% year-over-year to $490.0 million; the TTM figure through Jun 2026 stood at $490.0 million (up 54.53% YoY), while the FY2025 annual figure was $287.7 million, down 14.59% from the prior year.
• Total Non-Current Liabilities came in at $490.0 million for Q2 2026 at Adaptive Biotechnologies, up from $281.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $490.0 million in Q2 2026 to a low of $240.4 million in Q2 2023.
• Average Total Non-Current Liabilities over 5 years is $309.1 million, with a median of $287.7 million recorded in 2025.
• Year-over-year, Total Non-Current Liabilities dropped 15.63% in 2022 and surged 54.53% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $267.2 million in 2022, then dropped by 10.01% to $240.4 million in 2023, then soared by 40.13% to $336.9 million in 2024, then decreased by 14.59% to $287.7 million in 2025, then jumped by 70.31% to $490.0 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $490.0 million in Q2 2026, $281.7 million in Q1 2026, and $287.7 million in Q4 2025.